Patricia Kropf on Home Administration of Synribo for CML
Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).
Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).
In May 2014, the FDA approved home administration of the subcutaneous injection for patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to treatment with tyrosine-kinase inhibitors (TKIs).
Prior to the approval, patients had to travel to the clinic to receive their injections, which Kropf says was burdensome and inconvenient. The injections can be administered by the patients or caregivers.
Kropf adds that she anticipates seeing an expansion of Synribo prescriptions because of the approval.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
